Gant, C. M.
Oosterwijk, M. M.
Binnenmars, S. H.
Navis, G. J.
Haverkate, H.
Bakker, S. J. L.
Laverman, G. D.
Funding for this research was provided by:
Vifor Pharma (n.a.)
Article History
Received: 15 December 2021
Accepted: 18 May 2023
First Online: 16 August 2023
Declarations
:
: The study has been approved by local institutional review boards (METC-Twente, NL57219.044.16; METC-Groningen, 1009.68020), is registered in the Netherlands Trial Register (NTR trial code 5855) and is performed according to the guidelines of good clinical practice and the declaration of Helsinki as revised in 2008. All participants signed an informed consent form before participation.
: Not applicable.
: The authors declare no competing interests.